Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of cyclosporin A in early adverse-risk chronic lymphocytic leukemia
ISRCTN61297219Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2013
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Birmingham. Primary endpoint: Change in proliferation rate of CLL cells. Started Apr 2013; status: completed.
02
Drugs
cyclosporine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN61297219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61297219.